Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells

Cellular Immunology

Volumn 275, Issue 1-2, 2012, Pages 47-54

  Tse, Kathy W K ^a,c   Lin, Kevin B L ^a,d   Dang Lawson, May ^a   Guzman Perez, Angel ^b   Aspnes, Gary E ^b   Buckbinder, Leonard ^b   Gold, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c STEMCELL Technologies   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Akt; B cells; Cell migration; CXCL13; FAK; Integrin mediated adhesion; Marginal zone B cells; Pyk2; Sphingosine 1 phosphate

Indexed keywords

CHEMOATTRACTANT; CXCL13 CHEMOKINE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; FOCAL ADHESION KINASE INHIBITOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

4-AMINOBENZOIC ACID; ANIMALS; B-LYMPHOCYTES; CELL ADHESION; CELL LINE; CHEMOKINE CXCL13; CHEMOTACTIC FACTORS; CHEMOTAXIS; ENZYME ACTIVATION; FOCAL ADHESION KINASE 2; FOCAL ADHESION PROTEIN-TYROSINE KINASES; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; QUINOLONES; SPHINGOSINE; SULFONES;

EID: 84860572471     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.03.002     Document Type: Article

References (53)

1. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 2010, 237:264-283.
2. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 2010, 10:301-316.
3. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Ann. Rev. Immunol. 2005, 23:127-159.
4. Cyster J.G. B cell follicles and antigen encounters of the third kind. Nat. Immunol. 2010, 11:989-996.
5. Miyasaka M., Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat. Rev. Immunol. 2004, 4:360-370.
6. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
7. Martin F., Kearney J.F. Marginal-zone B cells. Nat. Rev. Immunol. 2002, 2:323-335.
8. Pillai S., Cariappa A., Moran S.T. Marginal zone B cells. Ann. Rev. Immunol. 2005, 23:161-196.
9. Lopes-Carvalho T., Kearney J.F. Development and selection of marginal zone B cells. Immunol. Rev. 2004, 197:192-205.
10. Lopes-Carvalho T., Kearney J.F. Marginal zone B cell physiology and disease. Curr. Dir. Autoimmun. 2005, 8:91-123.
11. Segundo C., Rodriguez C., Garcia-Poley A., Aguilar M., Gavilan I., Bellas C., Brieva J.A. Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments. Thyroid 2001, 11:525-530.
12. Wither J.E., Paterson A.D., Vukusic B. Genetic dissection of B cell traits in New Zealand black mice. The expanded population of B cells expressing up-regulated costimulatory molecules shows linkage to Nba2. Eur. J. Immunol. 2000, 30:356-365.
13. Marino E., Batten M., Groom J., Walters S., Liuwantara D., Mackay F., Grey S.T. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 2008, 57:395-404.
14. Attanavanich K., Kearney J.F. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 2004, 172:803-811.
15. high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J. Immunol. 1999, 162:7198-7207.
16. Wither J.E., Roy V., Brennan L.A. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice. Clin. Immunol. 2000, 94:51-63.
17. Kazkaz H., Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr. Opin. Pharmacol. 2004, 4:398-402.
18. Fiorina P., Vergani A., Dada S., Jurewicz M., Wong M., Law K., Wu E., Tian Z., Abdi R., Guleria I., Rodig S., Dunussi-Joannopoulos K., Bluestone J., Sayegh M.H. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 2008, 57:3013-3024.
19. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
20. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., Wu Y., Meng Y.G., Gribling P., Lin Z., Nguyen K., Tran T., Zhang Y., Rosen H., Martin F., Chan A.C. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 2005, 174:817-826.
21. Yu S., Dunn R., Kehry M.R., Braley-Mullen H. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 2008, 180:7706-7713.
22. Gelman I.H. Pyk 2 FAKs, any two FAKs. Cell Biol. Int. 2003, 27:507-510.
23. Mitra S.K., Hanson D.A., Schlaepfer D.D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 2005, 6:56-68.
24. Okigaki M., Davis C., Falasca M., Harroch S., Felsenfeld D.P., Sheetz M.P., Schlessinger J. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc. Natl. Acad. Sci. USA 2003, 100:10740-10745.
25. Ostergaard H.L., Lysechko T.L. Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell activation and function. Immunol. Res. 2005, 31:267-282.
26. Dikic I., Schlessinger J. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J. Biol. Chem. 1998, 273:14301-14308.
27. Tse K.W., Dang-Lawson M., Lee R.L., Vong D., Bulic A., Buckbinder L., Gold M.R. B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading. J. Biol. Chem. 2009, 284:22865-22877.
28. Freedman A.S., Rhynhart K., Nojima Y., Svahn J., Eliseo L., Benjamin C.D., Morimoto C., Vivier E. Stimulation of protein tyrosine phosphorylation in human B cells after ligation of the beta 1 integrin VLA-4. J. Immunol. 1993, 150:1645-1652.
29. Manie S.N., Astier A., Wang D., Phifer J.S., Chen J., Lazarovits A.I., Morimoto C., Freedman A.S. Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Blood 1996, 87:1855-1861.
30. Glodek A.M., Honczarenko M., Le Y., Campbell J.J., Silberstein L.E. Sustained activation of cell adhesion is a differentially regulated process in B lymphopoiesis. J. Exp. Med. 2003, 197:461-473.
31. Mlinaric-Rascan I., Yamamoto T. B cell receptor signaling involves physical and functional association of FAK with Lyn and IgM. FEBS Lett. 2001, 498:26-31.
32. Guinamard R., Okigaki M., Schlessinger J., Ravetch J.V. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 2000, 1:31-36.
33. Glodek A.M., Le Y., Dykxhoorn D.M., Park S.Y., Mostoslavsky G., Mulligan R., Lieberman J., Beggs H.E., Honczarenko M., Silberstein L.E. Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells. Leukemia 2007, 21:1723-1732.
34. Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C., Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L., Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N., Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M., Vajdos F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008, 68:1935-1944.
35. Bagi C.M., Roberts G.W., Andresen C.J. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer 2008, 112:2313-2321.
36. Slack-Davis J.K., Martin K.H., Tilghman R.W., Iwanicki M., Ung E.J., Autry C., Luzzio M.J., Cooper B., Kath J.C., Roberts W.G., Parsons J.T. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem. 2007, 282:14845-14852.
37. Buckbinder L., Crawford D.T., Qi H., Ke H.Z., Olson L.M., Long K.R., Bonnette P.C., Baumann A.P., Hambor J.E., Grasser W.A., Pan L.C., Owen T.A., Luzzio M.J., Hulford C.A., Gebhard D.F., Paralkar V.M., Simmons H.A., Kath J.C., Roberts W.G., Smock S.L., Guzman-Perez A., Brown T.A., Li M. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc. Natl. Acad. Sci. USA 2007, 104:10619-10624.
38. Jones M.L., Shawe-Taylor A.J., Williams C.M., Poole A.W. Characterization of a novel focal adhesion kinase inhibitor in human platelets. Biochem. Biophys. Res. Commun. 2009, 389:198-203.
39. Durand C.A., Westendorf J., Tse K.W., Gold M.R. The Rap GTPases mediate CXCL13- and sphingosine1-phosphate-induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes. Eur. J. Immunol. 2006, 36:2235-2249.
40. Durand C.A., Hartvigsen K., Fogelstrand L., Kim S., Iritani S., Vanhaesebroeck B., Witztum J.L., Puri K.D., Gold M.R. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 2009, 183:5673-5684.
41. Rieken S., Herroeder S., Sassmann A., Wallenwein B., Moers A., Offermanns S., Wettschureck N. Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11). J. Biol. Chem. 2006, 281:36985-36992.
42. Cinamon G., Matloubian M., Lesneski M.J., Xu Y., Low C., Lu T., Proia R.L., Cyster J.G. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol. 2004, 5:713-720.
43. Lu T.T., Cyster J.G. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 2002, 297:409-412.
44. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3:317-330.
45. Rickert P., Weiner O.D., Wang F., Bourne H.R., Servant G. Leukocytes navigate by compass: roles of PI3Kgamma and its lipid products. Trends Cell Biol. 2000, 10:466-473.
46. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
47. Hatch W.C., Ganju R.K., Hiregowdara D., Avraham S., Groopman J.E. The related adhesion focal tyrosine kinase (RAFTK) is tyrosine phosphorylated and participates in colony-stimulating factor-1/macrophage colony-stimulating factor signaling in monocyte-macrophages. Blood 1998, 91:3967-3973.
48. Beinke S., Phee H., Clingan J.M., Schlessinger J., Matloubian M., Weiss A. Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate. Proc. Natl. Acad. Sci. USA 2010, 107:16234-16239.
49. Tilghman R.W., Slack-Davis J.K., Sergina N., Martin K.H., Iwanicki M., Hershey E.D., Beggs H.E., Reichardt L.F., Parsons J.T. Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J. Cell Sci. 2005, 118:2613-2623.
50. Riol-Blanco L., Sanchez-Sanchez N., Torres A., Tejedor A., Narumiya S., Corbi A.L., Sanchez-Mateos P., Rodriguez-Fernandez J.L. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J. Immunol. 2005, 174:4070-4080.
51. Gismondi A., Jacobelli J., Strippoli R., Mainiero F., Soriani A., Cifaldi L., Piccoli M., Frati L., Santoni A. Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J. Immunol. 2003, 170:3065-3073.
52. Lim Y., Lim S.T., Tomar A., Gardel M., Bernard-Trifilo J.A., Chen X.L., Uryu S.A., Canete-Soler R., Zhai J., Lin H., Schlaepfer W.W., Nalbant P., Bokoch G., Ilic D., Waterman-Storer C., Schlaepfer D.D. Pyk2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility. J. Cell Biol. 2008, 180:187-203.
53. Chen H.C., Appeddu P.A., Isoda H., Guan J.L. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 1996, 271:26329-26334.